Allergan cites DTC spending as factor in strong Q2 results

Share this article:
Allergan cited strong spending behind DTC and detailing as factors in reporting stronger-than-expected Q2 results. The firm saw solid gains in its eyecare products, breast implants, medical devices for obesity and Botox for a 23% gain over Q2 2006.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...